Skip to main content

Human CX3CL1/Fractalkine Biotinylated Antibody

R&D Systems, part of Bio-Techne | Catalog # BAF365

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
BAF365

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human

Applications

Validated:

Western Blot

Cited:

Immunocytochemistry, Immunohistochemistry-Frozen

Label

Biotin

Antibody Source

Polyclonal Goat IgG

Product Specifications

Immunogen

E. coli-derived recombinant human CX3CL1/Fractalkine chemokine domain (R&D Systems, Catalog # 362-CX)
Gln25-Gly100
Accession # Q6I9S9

Specificity

Detects human CX3CL1/Fractalkine in Western blots. In this format, less than 5% cross-reactivity with recombinant mouse (rm) 6Ckine is observed and less than 2% cross-reactivity with recombinant human (rh) MCP-1, rhEotaxin, and rmEotaxin is observed.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Applications for Human CX3CL1/Fractalkine Biotinylated Antibody

Application
Recommended Usage

Western Blot

0.1 µg/mL
Sample: Recombinant Human CX3CL1/Fractalkine Chemokine Domain (Catalog # 362-CX)
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CX3CL1/Fractalkine

CX3CL1, also named neurotactin, is a novel chemokine identified through bioinformatics. CX3CL1 has a unique C-X3-C cysteine motif near the amino-terminus and is the first member of a fourth branch of the chemokine superfamily. Unlike other known chemokines, CX3CL1 is a type 1 membrane protein containing a chemokine domain tethered on a long mucin-like stalk. Human CX3CL1 cDNA encodes a 397 amino acid (aa) residue membrane protein with a 24 aa residue predicted signal peptide, a 76 aa residue chemokine domain, a 241 aa residue stalk region containing 17 degenerate mucin-like repeats, a 19 aa residue transmembrane segment and a 37 aa residue cytoplasmic domain. The extracellular domain of human CX3CL1 can be released, possibly by proteolysis at the dibasic cleavage site proximal to the membrane, to generate soluble CX3CL1. CX3CL1 mRNA has been detected in various tissues including the brain and heart. The expression of CX3CL1 was also reported to be up-regulated in endothelial cells and microglia by inflammatory signals. Membrane-bound CX3CL1 has been shown to promote adhesion of leukocytes. The soluble chemokine domain of human CX3CL1 was reported to be chemotactic for T cells and monocytes while the soluble chemokine domain of mouse CX3CL1 was reported to chemoattract neutrophils and T-lymphocytes but not monocytes. The gene for human CX3CL1 has been mapped to chromosome 16q.

References

  1. Pan, Y. et al. (1997) Nature 387:611.
  2. Bazan, J.F. et al. (1997) Nature 385:640.
  3. Mackay, C.R. (1997) Current Biology 7:R384.

Alternate Names

FKN, Fractalkine, Neurotactin

Entrez Gene IDs

6376 (Human); 20312 (Mouse); 89808 (Rat); 102117496 (Cynomolgus Monkey)

Gene Symbol

CX3CL1

UniProt

Additional CX3CL1/Fractalkine Products

Product Documents for Human CX3CL1/Fractalkine Biotinylated Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human CX3CL1/Fractalkine Biotinylated Antibody

For research use only

Loading...
Loading...
Loading...
Loading...